149 related articles for article (PubMed ID: 16607975)
1. The price of guidelines: revising the national guidelines for managing Australian women with abnormal pap smears.
Mitchell H
Sex Health; 2006 Mar; 3(1):53-5. PubMed ID: 16607975
[TBL] [Abstract][Full Text] [Related]
2. The short-term financial costs of abnormal Pap smears to women and government in Australia.
Kavanagh AM; Butler JR
Aust N Z J Public Health; 1998; 22(3 Suppl):347-52. PubMed ID: 9629821
[TBL] [Abstract][Full Text] [Related]
3. Resource use and cost analysis of managing abnormal Pap smears: a retrospective study in five countries.
Rash B; Martin-Hirsch P; Schneider A; Sideri M; Tan J; Torné A; Standaert B
Eur J Gynaecol Oncol; 2008; 29(3):225-32. PubMed ID: 18592784
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
5. Colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear.
Reed BD
Arch Fam Med; 1996; 5(10):582-4. PubMed ID: 8930230
[No Abstract] [Full Text] [Related]
6. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.
Flores Y; Shah K; Lazcano E; Hernández M; Bishai D; Ferris DG; Lörincz A; Hernández P; Salmerón J;
Salud Publica Mex; 2002; 44(4):335-44. PubMed ID: 12216521
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
8. Paying for prevention standardizing the measurement of the value of health care interventions.
Vasilev SA
Obstet Gynecol Clin North Am; 2002 Dec; 29(4):613-43, v. PubMed ID: 12509088
[TBL] [Abstract][Full Text] [Related]
9. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
[TBL] [Abstract][Full Text] [Related]
10. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
11. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
12. A cost-benefit analysis of colposcopy for cervical squamous intraepithelial lesions found on Papanicolaou smear.
Chesebro MJ; Everett WD
Arch Fam Med; 1996; 5(10):576-81. PubMed ID: 8930229
[TBL] [Abstract][Full Text] [Related]
13. Is a once-in-a-lifetime pap smear the best option for low-resourced settings?
Robles SC
Int J Cancer; 2004 Aug; 111(1):160-1; discussion 162. PubMed ID: 15185358
[No Abstract] [Full Text] [Related]
14. Cost--effectiveness of pap smear in Kermanshah, Iran.
Nokiani FA; Akbari H; Rezaei M; Madani H; Ale Agha ME
Asian Pac J Cancer Prev; 2008; 9(1):107-10. PubMed ID: 18439087
[TBL] [Abstract][Full Text] [Related]
15. Re: An alternative cost-effectiveness analysis of ThinPrep in the Australian setting.
Llewellyn H
Aust N Z J Obstet Gynaecol; 2006 Feb; 46(1):67. PubMed ID: 16441702
[No Abstract] [Full Text] [Related]
16. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
17. Management of the patient with an abnormal Papanicolaou smear.
Chirenje ZM
Cent Afr J Med; 1994 May; 40(5):131-4. PubMed ID: 7954725
[TBL] [Abstract][Full Text] [Related]
18. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective.
Giorgi-Rossi P; Segnan N; Zappa M; Naldoni C; Zorzi M; Confortini M; Merito M; Cuzick J; Ronco G;
Int J Cancer; 2007 Dec; 121(12):2729-34. PubMed ID: 17724715
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of new cytology technologies.
Hutchinson M; Farber FL
Am J Clin Pathol; 2000 Jan; 113(1):149-51. PubMed ID: 10631869
[No Abstract] [Full Text] [Related]
20. Outcome of women referred to colposcopy for persistently inadequate smears.
Sen C; Brett MT
Cytopathology; 2000 Feb; 11(1):38-44. PubMed ID: 10714374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
